This company has been acquired
LMNL Stock Overview
Liminal BioSciences Inc., a development stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Liminal BioSciences Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €8.50 |
| 52 Week High | €8.50 |
| 52 Week Low | €3.10 |
| Beta | 29.34 |
| 1 Month Change | 0.95% |
| 3 Month Change | 35.35% |
| 1 Year Change | 87.10% |
| 3 Year Change | -92.36% |
| 5 Year Change | -99.75% |
| Change since IPO | -99.24% |
Recent News & Updates
Recent updates
Liminal transfers to Nasdaq Capital Market, gets more time to comply with listing rule
Sep 02Liminal BioSciences ends CDMO agreement for $33M cost savings
Aug 25Liminal BioSciences discontinues fezagepras development
Jul 21FDA grants approval to Liminal BioSciences' Ryplazim treatment
Jun 04Liminal shares slide after plans to stop fezagepras development
May 28Liminal Biosciences subsidiary receives FDA nod for US-based plasma collection centre
Jan 12Liminal BioSciences Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 13FDA extends review period for Liminal Bio's Ryplazim application
Nov 09Shareholder Returns
| LMNL | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.4% | 0.2% | -0.2% |
| 1Y | 87.1% | -4.7% | 25.6% |
Return vs Industry: LMNL exceeded the US Biotechs industry which returned 10.3% over the past year.
Return vs Market: LMNL exceeded the US Market which returned 15.1% over the past year.
Price Volatility
| LMNL volatility | |
|---|---|
| LMNL Average Weekly Movement | 11.7% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 18.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: LMNL's share price has been volatile over the past 3 months.
Volatility Over Time: LMNL's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | n/a | Bruce Pritchard | www.liminalbiosciences.com |
Liminal BioSciences Inc., a development stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company is developing LMNL6511, a selective antagonist for the G-protein coupled receptor 84, is expected to commence a Phase 1 clinical trial. It is also developing potential OXER1 antagonists and GPR40 agonists, which are in preclinical stage.
Liminal BioSciences Inc. Fundamentals Summary
| LMNL fundamental statistics | |
|---|---|
| Market cap | US$13.05m |
| Earnings (TTM) | -US$28.06m |
| Revenue (TTM) | US$492.00k |
0.0x
P/S Ratio0.0x
P/E RatioIs LMNL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LMNL income statement (TTM) | |
|---|---|
| Revenue | CA$492.00k |
| Cost of Revenue | CA$15.49m |
| Gross Profit | -CA$15.00m |
| Other Expenses | CA$13.06m |
| Earnings | -CA$28.06m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -8.63 |
| Gross Margin | -3,048.17% |
| Net Profit Margin | -5,702.85% |
| Debt/Equity Ratio | 0% |
How did LMNL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/09/27 13:53 |
| End of Day Share Price | 2023/09/25 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Liminal BioSciences Inc. is covered by 15 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Doug Cooper | Beacon Securities Limited |
| Antonia Borovina | Bloom Burton & Co. |
| Dewey Steadman | Canaccord Genuity |